Cd44 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| CD44 Protein | |
|---|---|
| Protein Name | Cell Surface Glycoprotein CD44 |
| Gene Symbol | CD44 |
| UniProt ID | P16070 |
| Protein Length | 341 amino acids (standard isoform) |
| Molecular Weight | ~80-95 kDa (variable by isoform) |
| Cellular Location | Plasma membrane (type I transmembrane) |
| Protein Family | Immunoglobulin superfamily |
CD44 is a cell surface glycoprotein involved in cell-cell interactions, cell adhesion, and migration. It exists in multiple isoforms generated by alternative splicing and plays important roles in immune cell trafficking, synaptic plasticity, and neuroinflammation[1]. CD44 serves as the primary receptor for hyaluronic acid (HA), a key component of the extracellular matrix, and mediates numerous cell-matrix and cell-cell interactions critical for development, immune surveillance, and tissue homeostasis[2].
The CD44 protein contains several distinct structural domains:
CD44 exhibits remarkable molecular diversity through alternative splicing of the variable region. Over 20 isoforms have been described[4]:
| Isoform | Description | Expression | Function |
|---|---|---|---|
| CD44s | Standard isoform (no variant exons) | Ubiquitous | Basic adhesion, hematopoietic cells |
| CD44v3 | Contains v3 exon | Activated leukocytes, endothelium | Binds growth factors (FGF, VEGF) |
| CD44v6 | Contains v6 exon | Tumor cells, activated T cells | Metastasis, T cell activation |
| CD44v8-10 | Contains v8-v10 exons | Epithelial cells, neurons | Protection against oxidative stress |
| CD44v9 | Contains v9 exon | Tumor cells, activated microglia | Tumor progression, synaptic plasticity |
CD44's primary ligand is hyaluronic acid (HA), a glycosaminoglycan abundant in the extracellular matrix and cerebrospinal fluid[5]. The interaction between CD44 and HA:
CD44 functions as a signaling receptor that activates multiple intracellular pathways:
CD44 is critical for lymphocyte homing and immune cell trafficking:
In the central nervous system, CD44 is expressed on multiple cell types[11]:
| Cell Type | Expression Level | Function |
|---|---|---|
| Microglia | High | Phagocytosis, neuroinflammation |
| Astrocytes | Moderate | Matrix maintenance, scar formation |
| Neurons | Low-Medium | Synaptic plasticity, memory formation |
| Oligodendrocytes | Low | Myelin maintenance |
| Endothelial cells | High | BBB integrity, leukocyte trafficking |
CD44 is significantly upregulated in Alzheimer's disease brain and contributes to multiple disease mechanisms[13]:
Amyloid-beta interaction: CD44 mediates microglial binding to Aβ plaques, influencing both protective phagocytosis and inflammatory responses. Studies show that Aβ oligomers can induce CD44 expression on microglia, creating a positive feedback loop for neuroinflammation[14].
Blood-brain barrier dysfunction: CD44 on brain endothelial cells participates in leukocyte trafficking across the BBB during AD. Elevated CD44 correlates with BBB permeability and perivascular inflammation[15].
Synaptic plasticity impairment: In hippocampal neurons, CD44 overexpression disrupts dendritic spine morphology and synaptic transmission, contributing to memory deficits[16].
α-Synuclein interactions: CD44 on microglia binds to α-synuclein aggregates, mediating their clearance but also triggering inflammatory responses. Genetic studies suggest CD44 variants modify PD risk and progression[17].
Dopaminergic neuron vulnerability: The substantia nigra shows elevated CD44 expression in PD, particularly in regions with Lewy pathology. CD44 may influence dopaminergic neuron survival through modulation of oxidative stress responses[18].
Microglial activation: CD44-HA interactions promote microglial activation and pro-inflammatory cytokine release, contributing to chronic neuroinflammation in PD[19].
CD44 plays a critical role in immune cell trafficking into the CNS during MS[20]:
Motor neuron expression: CD44 is upregulated in ALS motor neurons and surrounding glia. Studies in SOD1 mouse models show CD44 expression increases disease progression, with CD44 knockout extending survival[21].
Glial scar formation: Reactive astrocytes in ALS upregulate CD44, contributing to the inhibitory environment that blocks axonal regeneration[22].
| Approach | Agent/Mechanism | Development Status | Notes |
|---|---|---|---|
| Blocking antibodies | Anti-CD44 mAbs | Preclinical | Prevents immune cell infiltration |
| HA-based decoys | Soluble CD44-HA mimetics | Research | Competes for ligand binding |
| Small molecule inhibitors | CD44 antagonists | Discovery | Target HA binding domain |
| Gene therapy | CD44 siRNA/shRNA | Preclinical | Reduces CD44 expression |
| Symptomatic | Hyaluronidase treatment | Research | Degrades HA to reduce CD44 activation |
The study of Cd44 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Aruffo A, et al. (1990). "CD44 is a principal cell surface receptor for hyaluronate." Cell 61(7):1303-1313. PMID:1694723 ↩︎
Ponta H, et al. (2003). "CD44: from adhesion molecules to signalling regulators." Nat Rev Mol Cell Biol 4(1):33-45. PMID:12511867 ↩︎
Tartour E, et al. (2011). "CatCD44s in cancer: a key regulator of tumor malignancy." Adv Cancer Res 111:1-32. PMID:21600571 ↩︎
表达调控与肿瘤转移的关系。Hou Y, et al. (2019). "CD44 alternative splicing in cancer." Oncogene 38(7):1099-1113. ↩︎
Jiang D, et al. (2011). "Hyaluronan in the extracellular matrix: signal from the cell surface." J Cell Biol 194(1):7-9. PMID:21746854 ↩︎
Kochlamazashvili G, et al. (2010). "The extracellular matrix molecule hyaluronic acid modulates hippocampal synaptic plasticity." J Neurosci 30(42):14006-14015. PMID:20962224 ↩︎
Cho HJ, et al. (2011). "CD44 promotes cell survival via EGFR activation." Cell Signal 23(8):1283-1293. PMID:21419249 ↩︎
Matzke A, et al. (2007). "CD44 induces NF-κB activation." J Immunol 179(6):3806-3815. PMID:17785813 ↩︎
DeGrendele HC, et al. (1997). "CD44 and its ligand hyaluronate mediate rolling." J Immunol 159(6):2549-2553. PMID:9300678 ↩︎
Friedl P, et al. (2000). "CD44 in leukocyte adhesion." Curr Top Microbiol Immunol 251:125-142. PMID:10806558 ↩︎
Moretto P, et al. (2006). "CD44 expression in the brain." J Neurosci Res 84(2):267-278. PMID:16681636 ↩︎
Avigdor A, et al. (2004). "CD44 and hyaluronic acid in stem cell recruitment." Exp Hematol 32(10):955-964. PMID:15521780 ↩︎
Bignami A, et al. (1992). "CD44 in Alzheimer's disease." Brain Res 591(2):331-338. PMID:1519290 ↩︎
Wright S, et al. (2019). "CD44-mediated microglial phagocytosis of amyloid-beta." Glia 67(8):1482-1495. PMID:30900342 ↩︎
Huang J, et al. (2020). "CD44 and blood-brain barrier dysfunction in AD." Neurobiol Dis 143:104981. PMID:32502678 ↩︎
Roszkowska M, et al. (2018). "CD44 regulates synaptic plasticity in hippocampus." Hippocampus 28(11):787-800. PMID:30208253 ↩︎
Kim S, et al. (2021). "CD44 polymorphisms and Parkinson's disease." Parkinsonism Relat Disord 83:42-48. PMID:33445098 ↩︎
Lee M, et al. (2020). "CD44 in the substantia nigra of PD." Mol Neurobiol 57(3):1692-1704. PMID:32036543 ↩︎
Halliwell B, et al. (2022). "Microglial CD44 and neuroinflammation in PD." J Neuroinflammation 19(1):54. PMID:35189876 ↩︎
Cannella B, et al. (1998). "CD44 in multiple sclerosis lesions." Brain Pathol 8(4):623-630. PMID:9804375 ↩︎
Turner BJ, et al. (2014). "CD44 in ALS: motor neuron and glial contributions." Brain 137(Pt 8):2277-2292. PMID:24893707 ↩︎
McGuckin C, et al. (2021). "CD44 and glial scar in ALS." Glia 69(5):1249-1263. PMID:33410204 ↩︎
Liu J, et al. (2023). "CD44 as therapeutic target in neurodegeneration." Nat Rev Drug Discov 22(4):287-304. PMID:37081234 ↩︎